Antares Pharma, Inc. (ATRS): Price and Financial Metrics

Antares Pharma, Inc. (ATRS)

Today's Latest Price: $3.12 USD

0.09 (2.97%)

Updated Nov 27 1:00pm

Add ATRS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

ATRS Stock Summary

  • Price to trailing twelve month operating cash flow for ATRS is currently 39.74, higher than 89.41% of US stocks with positive operating cash flow.
  • In terms of twelve month growth in earnings before interest and taxes, Antares Pharma Inc is reporting a growth rate of 415.74%; that's higher than 96.37% of US stocks.
  • As for revenue growth, note that ATRS's revenue has grown 36.68% over the past 12 months; that beats the revenue growth of 86.81% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Antares Pharma Inc are UEIC, SVM, SSTK, UCTT, and CARG.
  • ATRS's SEC filings can be seen here. And to visit Antares Pharma Inc's official web site, go to

ATRS Stock Price Chart Interactive Chart >

Price chart for ATRS

ATRS Price/Volume Stats

Current price $3.12 52-week high $5.13
Prev. close $3.03 52-week low $1.60
Day low $2.98 Volume 618,000
Day high $3.13 Avg. volume 1,222,962
50-day MA $2.96 Dividend yield N/A
200-day MA $2.83 Market Cap 520.02M

Antares Pharma, Inc. (ATRS) Company Bio

Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company was founded in 1979 and is based in Ewing, New Jersey.

ATRS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$3.12$0.01 -100%

We started the process of determining a valid price forecast for Antares Pharma Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Antares Pharma Inc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for ATRS, they are:

  • The company's compound free cash flow growth rate over the past 0.5 years comes in at -0.5%; that's greater than only 2.24% of US stocks we're applying DCF forecasting to.
  • As a business, Antares Pharma Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than merely 0% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Antares Pharma Inc? See AGHC, ALC, AMRN, MOR, and PACB.

ATRS Latest News Stream

Event/Time News Detail
Loading, please wait...

ATRS Latest Social Stream

Loading social stream, please wait...

View Full ATRS Social Stream

Latest ATRS News From Around the Web

Below are the latest news stories about Antares Pharma Inc that investors may wish to consider to help them evaluate ATRS as an investment opportunity.

Antares Pharma inks deal with Ferring Pharma for Nocdurna in U.S.

Antares Pharma (ATRS) has entered into an exclusive license agreement with Ferring Pharmaceuticals for the marketed product NOCDURNA (desmopressin acetate), which is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate, in the U.S. Under the terms of...

Seeking Alpha | October 1, 2020

Antares Pharma to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference

EWING, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced…

GlobeNewswire | September 8, 2020

Why Antares Pharma's Stock Is Trading Higher Today

Antares Pharma (NASDAQ: ATRS ) shares are trading higher on Monday after the company announced a deal with Lunatus Global to distribute and promote XYOSTED in Saudi Arabia. Antares Pharma … Full story available on

Benzinga | August 3, 2020

Antares Pharma to Report Second Quarter 2020 Operating and Financial Results

EWING, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced it will release its second quarter 2020 financial results and recent operating progress before the market opens on Thursday, August 6, 2020.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on August 6, 2020 to discuss the results. Interested parties may participate in the conference call by dialing 1-800-353-6461 or 1-334-323-0501 and entering access code 5888699.  We encourage interested parties to dial into the conference call at least 10 minutes prior to the scheduled start time.  A replay of the conference call will be available from 11:30 a.m. ET on Thursday, August 6, 2020 through 11:30 a.m. ET on Saturday, Sep...

Yahoo | July 30, 2020

First Commercial Product Using Antares Pharma’s Multi-Dose Pen Platform Launches in Europe

EWING, N.J., July 21, 2020 -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”), a pharmaceutical technology company, announced the first commercialization of the.

Yahoo | July 21, 2020

Read More 'ATRS' Stories Here

ATRS Price Returns

1-mo 14.29%
3-mo 10.25%
6-mo 9.09%
1-year -34.04%
3-year 68.65%
5-year 136.36%
YTD -33.62%
2019 72.79%
2018 36.68%
2017 -14.59%
2016 92.56%
2015 -52.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9285 seconds.